Overview

A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's Disease

Status:
Terminated

Trial end date:
2015-06-01

Target enrollment:

Participant gender:

Summary

This is a randomized, double-blind, placebo-controlled, multiple-ascending dose study of orally administered AVE8112 in patients with Parkinson's Disease (PD).

Phase:

Phase 1

Details

Lead Sponsor:

Michael J. Fox Foundation for Parkinson's Research

Collaborator:

Sanofi